The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea

Inclusion Criteria: * Subjects must be female 25-60 years of age with moderate facial rosacea at screening and 6 or 7 papules and/or pustules; as well as, no other known medical conditions that, in the investigator's opinion, may interfere with study participation. * Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant(R), Depo-Provera(R) double barrier methods (e.g., condom and spermacide) and abstinence. * Subjects must provide written informed consent. * Willingness to comply with the study design and procedures. * Subjects who agree to sign a photography release form. Exclusion Criteria: * Any dermatological disorder, except rosacea requiring the use of prescription medication, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin characteristics, * Subjects who are using any anti-aging skin care products within 4 weeks of study enrollment. * Subjects who are not willing to use only the assigned study products and nothing else, except for self-selected colored cosmetics that must remain unchanged during the study, to their face. * Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products. * Subjects, who are pregnant, breast feeding, or planning a pregnancy. * Subjects with clinically significant unstable medical disorders. * Subjects who are unwilling or unable to comply with the requirements of the protocol. * Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study. * Subjects who have participated in any clinical study in the past 30 days or are currently participating in any other clinical study. * Subjects with any planned surgeries and/or invasive medical procedures during the course of the study. * Subjects who started hormone replacement therapies (HRT) or hormones for birth control less than 3 months prior to study entry or who plan on starting, stopping, or changing doses of HRT or hormones for birth control during the study. * Subjects who currently or frequently use high doses of anti-inflammatory drugs for a defined medication condition. Aspirin use should not exceed 2 tablets (650 mg) per day. * Subjects currently receiving any anticancer, immunosuppressive treatments/ medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.), or radiation as determined by the initial paperwork. * Subjects with a history of immunosuppression/immune deficiency disorders (including (HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation.